🚀 𝗖𝗮𝗿𝗶𝗻𝗮™ 𝗣𝗹𝗮𝘁𝗳𝗼𝗿𝗺: 𝗔𝗱𝘃𝗮𝗻𝗰𝗶𝗻𝗴 𝗚𝗜 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝘆 𝘄𝗶𝘁𝗵 𝗣𝗿𝗲𝗰𝗶𝘀𝗶𝗼𝗻 & 𝗦𝗮𝗳𝗲𝘁𝘆 🥼

Proud to share results from “𝙎𝙝𝙤𝙧𝙩‑𝙩𝙚𝙧𝙢 𝙤𝙪𝙩𝙘𝙤𝙢𝙚 𝙖𝙣𝙖𝙡𝙮𝙨𝙞𝙨 𝙤𝙛 𝘾𝙖𝙧𝙞𝙣𝙖™ 𝙋𝙡𝙖𝙩𝙛𝙤𝙧𝙢 𝙞𝙣 𝙜𝙖𝙨𝙩𝙧𝙞𝙘 𝙖𝙣𝙙 𝙘𝙤𝙡𝙤𝙧𝙚𝙘𝙩𝙖𝙡 𝙨𝙪𝙧𝙜𝙚𝙧𝙮: 𝘼 𝙨𝙞𝙣𝙜𝙡𝙚‑𝙜𝙧𝙤𝙪𝙥 𝙩𝙖𝙧𝙜𝙚𝙩‑𝙫𝙖𝙡𝙪𝙚 𝙘𝙡𝙞𝙣𝙞𝙘𝙖𝙡 𝙩𝙧𝙞𝙖𝙡”, recently published in 𝗜𝗻𝘁𝗲𝗹𝗹𝗶𝗴𝗲𝗻𝘁 𝗦𝘂𝗿𝗴𝗲𝗿𝘆 𝗯𝘆 𝗞𝗲𝗔𝗶 ().

Congrats to 𝗣𝗿𝗼𝗳𝗲𝘀𝘀𝗼𝗿 𝗧𝗮𝗶𝘆𝘂𝗮𝗻 𝗟𝗶 and his team at the 𝗚𝗮𝘀𝘁𝗿𝗼𝗶𝗻𝘁𝗲𝘀𝘁𝗶𝗻𝗮𝗹 𝗦𝘂𝗿𝗴𝗶𝗰𝗮𝗹 𝗜𝗻𝘀𝘁𝗶𝘁𝘂𝘁𝗲 𝗼𝗳南昌大学! Give it a read here:https://lnkd.in/gQGnF85u.

Here’s why this is a win for our team and surgeons:

✅ 𝗭𝗲𝗿𝗼 𝗗𝗲𝘃𝗶𝗰𝗲-𝗥𝗲𝗹𝗮𝘁𝗲𝗱 𝗔𝗱𝘃𝗲𝗿𝘀𝗲 𝗘𝘃𝗲𝗻𝘁𝘀
• Across gastric and colorectal cases,话题标签#Carinaachieved target safety goals – no significant platform-related complications reported.

⏱️ 𝗘𝗳𝗳𝗶𝗰𝗶𝗲𝗻𝘁 𝗦𝗲𝘁𝘂𝗽 & 𝗢𝗽𝗲𝗿𝗮𝘁𝗶𝗼𝗻
• Median docking time: ~𝟲 𝗺𝗶𝗻𝘂𝘁𝗲𝘀, helping streamline OR turnover.
• Median operative duration: ~𝟭𝟴𝟬 𝗺𝗶𝗻𝘂𝘁𝗲𝘀, aligning well with industry standards for complex GI cases.

🔍 𝗢𝗻𝗰𝗼𝗹𝗼𝗴𝗶𝗰 𝗤𝘂𝗮𝗹𝗶𝘁𝘆 𝗘𝗻𝗱𝗽𝗼𝗶𝗻𝘁𝘀 𝗛𝗶𝘁
• R0 resection rate: an impressive 𝟭𝟬𝟬%, ensuring no residual tumor at margins.
• Average lymph node yield: 𝟮𝟱 𝗻𝗼𝗱𝗲𝘀, meeting – and exceeding – the expected benchmark for robust oncologic staging.

💡 𝗖𝗹𝗶𝗻𝗶𝗰𝗮𝗹 & 𝗧𝗲𝗮𝗺 𝗖𝗼𝗻𝗳𝗶𝗱𝗲𝗻𝗰𝗲 𝗕𝗼𝗼𝘀𝘁𝗲𝗱
• Surgeons reported smooth ergonomics and consistent platform stability throughout procedures.

Seeing our system excel in GI oncology validates our commitment to 𝗳𝗹𝗲𝘅𝗶𝗯𝗶𝗹𝗶𝘁𝘆, 𝗮𝗱𝗮𝗽𝘁𝗮𝗯𝗶𝗹𝗶𝘁𝘆, and 𝗮𝗳𝗳𝗼𝗿𝗱𝗮𝗯𝗶𝗹𝗶𝘁𝘆. Next stop: broader adoption and tougher cases! 💪